Cipla has firmed up a joint venture in Iran – a market where it hopes to maintain leadership position despite some tension surrounding the nuclear deal between the P5+1 global powers and the Middle Eastern nation.
Cipla Ltd. expects to invest around €17m in a joint venture in Iran. The Indian firm has had a long-term business relationship in Iran and appears keen to build further momentum there.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
CEO Len Schleifer explained on the company’s Q1 earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
CEO Len Schleifer explained on the company’s Q1 earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
